Adynxx, Inc. announced On May 3, 2019, immediately prior to the Effective Time, David Johnson company Chief Executive Officer, resigned as an executive officer. On May 3, 2019, following the Effective Time of the Merger companyr board of directors appointed Rick Orr as company Chief Executive Officer (principal executive and financial officer), Donald Manning, M.D., Ph.D., as company Chief Medical Officer, and Julien Mamet, Ph.D. as company Chief Scientific Officer. There are no family relationships among any of company directors and executive officers. Biographical information regarding each of Mr. Orr, Dr. Manning and Dr. Mamet is included in company Definitive Proxy Statement on Schedule 14A, filed with the SEC on January 24, 2019, or the Proxy Statement, and is incorporated herein by reference.